Mimedx (MDXG) EBITDA Margin (2011 - 2026)

Mimedx (MDXG) posted EBITDA Margin of 28.69% for Q2 2026, down 5.46% sequentially from 27.21% in Q1 2026, and down 4124.0% YoY from 0.71% in Q2 2025.

Mimedx (MDXG) EBITDA Margin (2011 - 2026) Analysis & Trends

Mimedx has reported EBITDA Margin for 16 years, with the latest figure at 28.69% in Q2 2026.

Quarterly EBITDA Margin fell 4124.0% year-over-year to 28.69% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 2.46% (down 931.0% YoY) and the FY2025 annual result came in at 15.26%, down 161.0% from the prior year.
EBITDA Margin fell to 28.69% in Q2 2026 per MDXG's latest filing, from 27.21% in the prior quarter.
Over five years, EBITDA Margin peaked at 26.89% in Q2 2024 and troughed at 28.69% in Q2 2026.
A 5-year average of 4.99% and a median of 12.91% in 2025 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2023 and 2026: EBITDA Margin surged 2775 bps in 2023, then tumbled 4124 bps in 2026.
Over 5 years, EBITDA Margin stood at 15.21% in 2022, then increased by 17 bps to 17.84% in 2023, then slumped by 33 bps to 11.9% in 2024, then jumped by 50 bps to 17.85% in 2025, then plunged by 261 bps to 28.69% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 28.69%, 27.21%, and 17.85% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	-28.69%

Download Data